Vitamin K2 (MK-7): From Lab Bench to Label Claim — A Formulator's Evidence Guide

Netherlands — 18 May 2026

For years, Vitamin D3 has been lauded as the panacea for bone health and immune support, often appearing in formulations as a standalone or paired with calcium. But is this approach fundamentally flawed? Emerging evidence suggests that without its synergistic partner, Vitamin K2 (specifically MK-7), the full benefits of D3 — particularly concerning cardiovascular health — remain unrealised, and potentially, D3 supplementation could even exacerbate certain risks. Why, then, do so many popular multivitamin and D3 supplements continue to neglect or underdose this critical nutrient?

What the Clinical Evidence Actually Shows

The interplay between Vitamin D3 and K2 is increasingly clear, especially regarding calcium metabolism. D3 promotes calcium absorption, but K2 (menaquinone-7) is crucial for directing that calcium to where it’s needed most: the bones and teeth, preventing its deposition in soft tissues like arteries. The Rotterdam Study, a landmark population-based cohort study, demonstrated a significant inverse association between high dietary intake of K2 and severe aortic calcification, as well as reduced risk of coronary heart disease. Doses used in intervention trials vary, but several studies investigating arterial stiffness and elasticity have employed 180 mcg to 360 mcg of MK-7 daily over periods of three years, showing promising results in reducing arterial stiffness in postmenopausal women. However, a recent meta-analysis highlighted the need for more large-scale, long-term randomised controlled trials to definitively establish optimal dosages and effect sizes across diverse populations. "While the mechanistic rationale is compelling, proving clinical outcomes at an individual level requires rigorous, placebo-controlled studies that are both expensive and lengthy," notes Dr. Eleonore Dubois, a nutritional biochemist at Wageningen University. "The industry must be careful not to outpace the science with its marketing claims."

The Formulation Reality

Formulating with MK-7 presents several challenges. The all-trans isomer of MK-7 is considered the most biologically active form, but stability can be an issue, particularly when exposed to light, heat, and certain minerals like iron and magnesium often found in multivitamins. Microencapsulated forms offer superior stability and mask potential off-notes, ensuring a longer shelf life and consistent dosage delivery. Bioavailability is generally good for MK-7 due to its longer half-life compared to MK-4, allowing for once-daily dosing. However, formulators must consider excipient interactions; some common fillers and binders can compromise stability or absorption. For instance, the presence of certain fatty acids can enhance absorption, whereas oxidative environments can degrade the active compound. Sourcing also matters; synthetic MK-7 is widely available, but fermented natto-derived extracts offer a natural alternative, though often at a higher cost and with potential allergen considerations. Minimum Order Quantities (MOQs) for high-quality, stable MK-7 can be substantial, often starting at 50 kg for a pure ingredient, which can be a barrier for smaller brands.

Market Position and Commercial Viability

The global Vitamin K2 market is projected to reach approximately £250 million by 2028, growing at a Compound Annual Growth Rate (CAGR) of around 15%. This growth is largely driven by increasing consumer awareness of its bone and cardiovascular health benefits, and its synergistic role with Vitamin D. Pricing for MK-7 remains relatively high compared to other fat-soluble vitamins, typically ranging from £800 to £1,500 per kilogram for a high-purity, stable form. This translates to a significant raw material cost for effective daily doses. "The challenge for brands is to justify the higher retail price point that reflects the cost of efficacious K2 levels," states Mr. Julian Thorne, a senior analyst at Nutraceutical Insights. "Consumers are becoming more discerning, but educating them on the value proposition of a well-dosed D3/K2 combination is key to achieving healthy margins, which typically sit between 40-60% for premium finished goods." Brands must also navigate the competitive landscape, where a few established ingredient suppliers dominate the market, influencing lead times and pricing structures.

What This Means for Netherlands

The Netherlands, with its health-conscious population and relatively advanced regulatory framework, represents a significant market for D3 and K2 combinations. The Dutch Food and Consumer Product Safety Authority (NVWA) adheres closely to EFSA guidelines regarding safety and permitted health claims. While specific claims for K2 are not as robust as for D3, general bone health and cardiovascular support claims are permissible when substantiated. Consumer demand for 'clean label' and scientifically backed products is strong here, presenting an opportunity for brands that can effectively communicate the D3/K2 synergy. However, the market is also saturated with lower-cost, underdosed D3 products, meaning differentiation through quality and efficacy is paramount. There is a clear appetite for premium, evidence-led formulations, particularly among demographics concerned with healthy ageing.

The Bottom Line for Formulators

Formulators should absolutely invest in Vitamin K2 (MK-7), particularly when pairing it with Vitamin D3. The scientific rationale for its inclusion at efficacious doses (e.g., 180 mcg+) is compelling, offering a distinct commercial advantage in a crowded market. However, this must be done with careful consideration of ingredient stability, sourcing high-quality all-trans MK-7, and educating the consumer to justify the premium. Underdosing K2 is a missed opportunity and potentially undermines the full benefit of D3 supplementation.